Join the 'Byvalson' group to help and get support from people like you.
Posted 20 Jun 2016 by Drugs.com
MONDAY, June 20, 2016 – Doctors who accept free meals from drug companies are more likely to prescribe the brand-name drugs those companies sell, a new study suggests. Physicians who received just one free meal, valued at less than $20 on average, were up to two times more likely to prescribe a promoted brand-name drug than a cheaper generic alternative, compared with doctors who did not accept a meal, the study found. Doctors who received multiple meals were up to three times more likely to prescribe these drugs. "To my surprise, tiny, tiny payments are associated with big differences in prescribing," said study author Colette DeJong, a research fellow at University of California San Francisco's (UCSF) Center for Healthcare Value. Additional meals and pricier fare were linked with even higher prescribing rates of the promoted drug. "So whether you get zero, one, two, three or four ... Read more
Related support groups: Pristiq, Benicar, Crestor, Bystolic, Azor, Benicar HCT, Rosuvastatin, Nebivolol, Olmesartan, Desvenlafaxine, Tribenzor, Diagnosis and Investigation, Byvalson, Amlodipine/Olmesartan, Hydrochlorothiazide/Olmesartan, Amlodipine/hydrochlorothiazide/olmesartan, Khedezla, Nebivolol/valsartan
Posted 16 Jun 2016 by Drugs.com
DUBLIN, June 6, 2016 /PRNewswire/ – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the approval of Byvalson (nebivolol and valsartan) 5 mg/ 80 mg tablets, by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension to lower blood pressure. Byvalson is the first and only fixed-dose combination (FDC) of a beta blocker (BB) and angiotensin II receptor blocker (ARB) available in the U.S. "Achieving blood pressure control is critical to reducing the risk of serious and life-threatening cardiovascular events. There remains a need for new therapies, as observed by the nearly half of patients in the U.S. who remain uncontrolled," said David Nicholson, Chief R&D Officer at Allergan. "We are pleased with the FDA approval of Byvalson, which will provide physicians a new fixed dose combination therapy treatment option for patients affected ... Read more